Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lonza : Showcases New SYNETH Product Range of Polyglycerol Esters for Perfect Balance of Function, Aesthetics and Mildness

share with twitter share with LinkedIn share with facebook
share via e-mail
05/08/2019 | 09:53am EDT

Morristown - At NYSCC Suppliers' Day 2019, Lonza is showcasing its new SYNETH product range of polyglycerol esters, extremely versatile non-ionic emulsifiers and surfactants that help formulators strike the perfect balance between functionality, aesthetics and mildness.

NYSCC Suppliers' Day takes place today and 8 May in New York City, NY (USA). Lonza will be at Booth 1611.

Launched at in-cosmetics Global, the SYNETHTM product range is based on a unique and customizable polyglycerol ester chemistry. It provides key formulation properties and enables formulation without compromise.

'We designed the SYNETHTM product range to help formulators address consumers' desire to care for their bodies and the environment while meeting their demands for innovative, luxurious products,' said Jennifer Clancy, Lonza Senior Director of Global Marketing. 'We developed the SYNETH product range from a single, versatile and customizable chemistry to increase formulation efficiency and speed to market.'

Versatility Across the Range

The SYNETHTM polyglycerol esters offer formulators a complete tool kit of emulsifiers and surfactants for virtually any application or product form in beauty and personal care, ranging from cleansers to emulsification of water/oil (w/o) emulsions.

The SYNETH emulsifiers/surfactants can be used in a range of leave-on and rinse-off applications for skin, hair and scalp care.

With Hydrophile-Lipophile Balance (HLB) values ranging from 3 to 15, the SYNETH product range comprises seven polyglycerol esters: SYNETH O3, a versatile, emulsifier/surfactant with a low HLB value, is ideal for use as a hydrophobic co-surfactant and in pigment wetting and dispersion.

SYNETH S8, a surfactant/emulsifier suitable for both (w/o) and oil/water (o/w) systems, is ideal for creating rich and luxurious textures in moisturizing leave-on and rinse-off applications.

SYNETH S10, a mid-range HLB (o/w) and (w/o) emulsifier, is ideal for moisturizing leave-on applications with unique textures across a wide range of viscosities.

SYNETH P11, a mid-range HLB emulsifier for high yield strength (w/o) and (o/w) systems, is ideal for creating luxurious textures for moisturizing leave-on applications, also across a wide range of viscosities.

SYNETH O13, a versatile and cold-processable surfactant/emulsifier, works for elegant, moisturizing leave-on and rinse-off applications.

SYNETH C15 is a cold-processable surfactant exhibiting exemplary mildness, flash foaming and oil pickup properties. It works well in gentle cleansing applications in hair and skin care.

SYNETH L15, a cold-processable surfactant with exemplary mildness and cleaning properties, works for gentle cleansing applications.

Mildness and Moisturization

SYNETHTM polyglycerol esters show excellent mildness on both skin and eyes, which makes them particularly useful in products for sensitive skin or infants and children.

'While superior mildness is a major advantage of any surfactant or emulsifier, SYNETHTM polyglycerol esters go a step further by providing active moisturization benefits,' Clancy said.

The SYNETHTM product range is naturally derived from plant origin and is fully compliant with the following criteria and standards: Non-PGE; Non-GMO, EO-, PO-, and 1,4-dioxane-free; Kosher, Halal and Vegan. The SYNETH product range complies with COSMOS and ISO 16128-1 standards and is RSPO MB-certified. The products are China Compliant with the exception of SYNETHTM C15 and P11.

'SYNETHTM polyglycerol esters provide cleansing performance and foaming characteristics previously considered impossible from a non-ionic surfactant,' said Daan Thorn Leeson, PhD, Global Head of Skin Care Technology. 'They also enable formulators to provide excellent aesthetics and innovative textures for leave-on systems without resorting to silicone-based ingredients that have come under great environmental and regulatory scrutiny.'

Processability and Formulation Efficiency

'Lonza's SYNETHTM product range of polyglycerol esters can help formulators increase speed to market in a number of ways,' Dr. Thorn Leeson said. 'First, relying on a single chemistry for an immensely broad range of applications with a large set of high-quality and relevant data available will help formulators cut product development time and improve formulation efficiency.'

He added, 'All SYNETHTM polyglycerol esters are either cold-processable or can be processed at low temperatures, which facilitates and speeds up lab batch preparation and scale-up.'

Given their multifunctional capabilities, functionality, stability and rheology control while providing additional moisturization benefits, the SYNETHTM product range of polyglycerol esters allows formulators to simplify formulations without compromising on aesthetics and performance.

About Lonza Consumer Product Ingredients - Personal Care

At Lonza Home & Personal Care, we are pushing the boundaries of science to help brand leaders and product innovators around the world to create cleaner, healthier and more effective products to meet the demands of today's consumers. Through our Science of Gorgeous Service, we help visionary Personal Care formulators and manufacturers offer value-driven consumers an extensive portfolio of innovative skin-, scalp- and hair-care technologies.

We are a leading supplier of non-traditional and traditional functional solutions, including next-generation preservatives, chassis ingredients, aesthetic modifiers and bioactives.

Working at the frontier of skin-care science, which is no longer bound by conventional chemistry, methods and technology, we equip developers aspiring to reduce the appearance of visible aging and the environment, enhance skin tone and maintain skin at its healthiest state. Following our holistic approach, we provide the means to protect, maintain and restore scalp health.

With strong capabilities in large and small molecules, as well as biotechnology, we unleash the power of cosmetics to help brands create innovative products that meet every consumer expectation.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.


Charlie Gins

Tel +1 201 316-9497

Email: charlie.gins@lonza.com

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGXST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forwardlooking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this release.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LONZA GROUP
08/15LONZA : Highlights Cutting-Edge Clean-Label Solutions to Welcome a Healthy Futur..
08/08LONZA : Welcomes Healthy Future for Brazilian Dietary Supplements Market at Fi S..
08/01Blue-blooded crabs at heart of pharma dispute on drug testing
07/24Lonza on Track to Deliver Full-Year 2019 Results, Driven by Pharma Biotech Bu..
07/24Lonza Expands Bioconjugation Facility and Announces Approval of Third Commerc..
07/11LONZA : Showcases Innovative Solutions to Make More Possible at the 14th Interna..
07/02LONZA : to Acquire Sterile Fill and Finish Facility from Novartis
07/01LONZA : Announces Short, Routine Shutdown of Niacinamide Plant in Nansha for Mai..
07/01Lonza fills portfolio hole by buying Novartis drug bottling plant
06/26LONZA : Launches the First in a Series of Educational Videos on 'Keeping Our Wor..
More news
Financials (CHF)
Sales 2019 5 915 M
EBIT 2019 1 206 M
Net income 2019 737 M
Debt 2019 3 284 M
Yield 2019 0,83%
P/E ratio 2019 35,3x
P/E ratio 2020 29,1x
EV / Sales2019 4,91x
EV / Sales2020 4,54x
Capitalization 25 778 M
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 363,97  CHF
Last Close Price 347,20  CHF
Spread / Highest target 33,1%
Spread / Average Target 4,83%
Spread / Lowest Target -39,5%
EPS Revisions
Richard Ridinger Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP34.43%26 363
CELLTRION, INC.--.--%16 143